Genitourinary Cancers | Specialty

mRCC: Identifying and Managing AEs in TKIs and IO Therapy

March 29th 2019

Role of TKIs in Intermediate or Poor-Risk mRCC

March 29th 2019

Favorable-Risk mRCC: Choosing Appropriate Frontline Therapy

March 29th 2019

Risk Stratification in Metastatic Renal Cell Carcinoma

March 29th 2019

Fox Chase Investigates Screening Methods to Avoid Unnecessary Radical Cystectomy

March 28th 2019

Currently, there is no reliable way to identify who can safely avoid radical cystectomy following MIBC treatment. For this reason, Fox Chase Cancer Center researchers are trying to find the as-yet-elusive 30% by asking 3 important questions.

Enfortumab Vedotin Active After Chemo and Immunotherapy in Urothelial Carcinoma

March 28th 2019

Enfortumab vedotin showed strong clinical activity in patients with locally advanced or metastatic urothelial carcinoma who previously received both platinum-containing chemotherapy and immune checkpoint therapy, according to topline results from the pivotal phase II EV-201 trial.

Dr. Somer on Optimal Combinations in mRCC

March 27th 2019

Bradley G. Somer, MD, an associate professor of hematology/oncology and head of strategic expansion/development at the University of Tennessee West Cancer Center, discusses optimal combinations for the treatment of patients with metastatic renal cell carcinoma (mRCC) in the frontline setting.

Dr. Quinn on Targetable Molecular Pathways in RCC

March 26th 2019

David I. Quinn, MBBS, PhD, associate professor of medicine, section head, Genitourinary Oncology, Division of Cancer Medicine and Blood Diseases, USC Keck School of Medicine, discusses targetable molecular pathways in renal cell carcinoma.

Bladder Cancer Guidelines Showcase Advent of Immunotherapy

March 24th 2019

Thomas W. Flaig, MD, discusses the latest updates to the NCCN guidelines for the treatment of patients with muscle-invasive bladder cancer and highlights the latest approvals of checkpoint inhibitors in this patient population.

Dr. Sznol on Unanswered Questions With Immunotherapy in RCC

March 22nd 2019

Mario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses unanswered questions with immunotherapy in the treatment of patients with renal cell carcinoma.

Frontline Combos Poised to Change NCCN Guidelines in Advanced RCC

March 22nd 2019

The 2019 National Comprehensive Cancer Network guideline on the management of advanced clear cell renal cell carcinoma undergoes a major shift in risk category used to define preferred and alternative first-line treatments.

Exploring the Role of Cytoreductive Nephrectomy in RCC

March 22nd 2019

Brian M. Shuch, MD, highlights the complex data with cytoreductive nephrectomy in renal cell carcinoma and offers advice on how to navigate the intricate treatment landscape.

Dr. Bochner on Molecular Profiling in Bladder Cancer

March 22nd 2019

Bernard H. Bochner, MD, FACS, chair of surgery, Memorial Sloan Kettering Cancer Center, discusses the importance of molecular profiling in the treatment of patients with bladder cancer.

Sznol Highlights Immunotherapy Advances in RCC

March 20th 2019

Mario Sznol, MD, highlights recent advances made with immunotherapy in renal cell carcinoma and sheds light on what the future may hold.

Pembrolizumab/Axitinib Favored as Frontline Standard in mRCC

March 20th 2019

Thomas Powles, MBBS, MRCP, MD, highlights key takeaways from pivotal trials and discusses how they impact the ever-changing landscape of metastatic renal cell carcinoma.

Dr. George on Dosing TKIs in RCC

March 20th 2019

Daniel J. George, MD, professor of Medicine and Surgery, member, Duke Cancer Institute, discusses the importance of dosing TKIs properly in patients with renal cell carcinoma (RCC).

Atezolizumab Shows Comparable Real-World Tolerability, Efficacy in Urothelial Carcinoma

March 19th 2019

Atezolizumab (Tecentriq) demonstrated consistent safety and efficacy with prior studies of the PD-L1 inhibitor in patients with locally advanced or metastatic urothelial carcinoma, including clinically relevant subgroups reflective of real-world clinical practice.

Dr. Shuch on Role of Cytoreductive Nephrectomy in RCC

March 19th 2019

Brian M. Shuch, MD, director of the Kidney Cancer Program, Alvin & Carrie Meinhardt Endowed Chair of Kidney Cancer Research, University of California, Los Angeles Institute of Urologic Oncology, discussed the role of cytoreductive nephrectomy in renal cell carcinoma.

Rini Discusses Future of Tivozanib, TKI/Immunotherapy Combos in mRCC

March 19th 2019

Brian I. Rini, MD, discusses the next steps with tivozanib (Fotivda) and immunotherapy/TKI combinations in patients with metastatic renal cell carcinoma.

Dr. Powles on the Results of the KEYNOTE-426 Trial in mRCC

March 15th 2019

Thomas Powles, MBBS, MRCP, MD, director, Barts Cancer Institute, discusses the results of the KEYNOTE-426 trial in metastatic renal cell carcinoma (mRCC).